Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery?

Insulin therapy plays an essential role in the treatment of diabetes mellitus. However, frequent injections required to effectively control the glycemic levels lead to substantial inconvenience and low patient compliance. In order to improve insulin delivery, many efforts have been made, such as dev...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting Zhang (Author), James Zhenggui Tang (Author), Xiaofan Fei (Author), Yanping Li (Author), Yi Song (Author), Zhiyong Qian (Author), Qiang Peng (Author)
Format: Book
Published: Elsevier, 2021-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a20d0dbea3614e11bcf90bff10671191
042 |a dc 
100 1 0 |a Ting Zhang  |e author 
700 1 0 |a James Zhenggui Tang  |e author 
700 1 0 |a Xiaofan Fei  |e author 
700 1 0 |a Yanping Li  |e author 
700 1 0 |a Yi Song  |e author 
700 1 0 |a Zhiyong Qian  |e author 
700 1 0 |a Qiang Peng  |e author 
245 0 0 |a Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery? 
260 |b Elsevier,   |c 2021-03-01T00:00:00Z. 
500 |a 2211-3835 
500 |a 10.1016/j.apsb.2020.08.016 
520 |a Insulin therapy plays an essential role in the treatment of diabetes mellitus. However, frequent injections required to effectively control the glycemic levels lead to substantial inconvenience and low patient compliance. In order to improve insulin delivery, many efforts have been made, such as developing the nanoparticles (NPs)-based release systems and oral insulin. Although some improvements have been achieved, the ultimate results are still unsatisfying and none of insulin-loaded NPs systems have been approved for clinical use so far. Recently, nano‒protein interactions and protein corona formation have drawn much attention due to their negative influence on the in vivo fate of NPs systems. As the other side of a coin, such interactions can also be used for constructing advanced drug delivery systems. Herein, we aim to provide an insight into the advance and flaws of various NPs-based insulin delivery systems. Particularly, an interesting discussion on nano‒protein interactions and its potentials for developing novel insulin delivery systems is initiated. 
546 |a EN 
690 |a Insulin 
690 |a Diabetic 
690 |a Nanomaterials 
690 |a Absorption 
690 |a Controlled release 
690 |a Protein adsorption 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Acta Pharmaceutica Sinica B, Vol 11, Iss 3, Pp 651-667 (2021) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2211383520307000 
787 0 |n https://doaj.org/toc/2211-3835 
856 4 1 |u https://doaj.org/article/a20d0dbea3614e11bcf90bff10671191  |z Connect to this object online.